171 related articles for article (PubMed ID: 29654782)
21. Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies.
Michel MC; Gravas S
Expert Opin Drug Saf; 2016 May; 15(5):647-57. PubMed ID: 26954275
[TBL] [Abstract][Full Text] [Related]
22. Mirabegron induces relaxant effects via cAMP signaling-dependent and -independent pathways in detrusor smooth muscle.
Maki T; Kajioka S; Itsumi M; Kareman E; Lee K; Shiota M; Eto M
Low Urin Tract Symptoms; 2019 Apr; 11(2):O209-O217. PubMed ID: 30632283
[TBL] [Abstract][Full Text] [Related]
23. beta(2) and beta(3)-adrenoceptor inhibition of alpha(1)-adrenoceptor-stimulated Ca(2+) elevation in human cultured prostatic stromal cells.
Haynes JM
Eur J Pharmacol; 2007 Sep; 570(1-3):18-26. PubMed ID: 17617401
[TBL] [Abstract][Full Text] [Related]
24. Combined treatment with a β
Imamura T; Ogawa T; Minagawa T; Nagai T; Suzuki T; Saito T; Yokoyama H; Nakazawa M; Ishizuka O
Neurourol Urodyn; 2017 Apr; 36(4):1026-1033. PubMed ID: 27367573
[TBL] [Abstract][Full Text] [Related]
25. The novel compound MP407 inhibits platelet aggregation through cyclic AMP-dependent processes.
Lin CS; Chen TH; Lin IH; Lee AR; Chou TC
Eur J Pharmacol; 2017 Nov; 815():324-331. PubMed ID: 28939294
[TBL] [Abstract][Full Text] [Related]
26. Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production.
Jeng JH; Wu HL; Lin BR; Lan WH; Chang HH; Ho YS; Lee PH; Wang YJ; Wang JS; Chen YJ; Chang MC
Atherosclerosis; 2007 Apr; 191(2):250-8. PubMed ID: 16797553
[TBL] [Abstract][Full Text] [Related]
27. Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin.
Aizawa N; Homma Y; Igawa Y
Eur Urol; 2012 Dec; 62(6):1165-73. PubMed ID: 22981677
[TBL] [Abstract][Full Text] [Related]
28. A functional analysis of the influence of β3-adrenoceptors on the rat micturition cycle.
Sadananda P; Drake MJ; Paton JF; Pickering AE
J Pharmacol Exp Ther; 2013 Nov; 347(2):506-15. PubMed ID: 24008334
[TBL] [Abstract][Full Text] [Related]
29. Mirabegron, A Selective β3-Adrenoceptor Agonist Causes an Improvement in Erectile Dysfunction in Diabetic Rats.
Yilmaz-Oral D; Kaya-Sezginer E; Askin D; Hamurtekin Y; Gur S
Exp Clin Endocrinol Diabetes; 2021 Mar; 129(4):296-302. PubMed ID: 30978726
[TBL] [Abstract][Full Text] [Related]
30. An Exploratory Study in Healthy Male Subjects of the Mechanism of Mirabegron-Induced Cardiovascular Effects.
van Gelderen M; Stölzel M; Meijer J; Kerbusch V; Collins C; Korstanje C
J Clin Pharmacol; 2017 Dec; 57(12):1534-1544. PubMed ID: 28618007
[TBL] [Abstract][Full Text] [Related]
31. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
[TBL] [Abstract][Full Text] [Related]
32. β3-Adrenoceptor-mediated relaxation of rat and human urinary bladder: roles of BKCa channels and Rho kinase.
Cernecka H; Kersten K; Maarsingh H; Elzinga CR; de Jong IJ; Korstanje C; Michel MC; Schmidt M
Naunyn Schmiedebergs Arch Pharmacol; 2015 Jul; 388(7):749-59. PubMed ID: 25956403
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome.
Rosa GM; Ferrero S; Nitti VW; Wagg A; Saleem T; Chapple CR
Eur Urol; 2016 Feb; 69(2):311-23. PubMed ID: 26422675
[TBL] [Abstract][Full Text] [Related]
34. Video-urodynamic effects of mirabegron, a β3 -adrenoceptor agonist, in patients with low-compliance bladder.
Kamei J; Furuta A; Akiyama Y; Niimi A; Ichihara K; Fujimura T; Fukuhara H; Kume H; Homma Y; Igawa Y
Int J Urol; 2015 Oct; 22(10):956-61. PubMed ID: 26177781
[TBL] [Abstract][Full Text] [Related]
35. Difference of (Ca2+)i movements in platelets stimulated by thrombin and TRAP: the involvement of alpha(IIb)beta3-mediated TXA2 synthesis.
Aoki T; Tomiyama Y; Honda S; Senzaki K; Tanaka A; Okubo M; Takahashi F; Takasugi H; Seki J
Thromb Haemost; 1998 Jun; 79(6):1184-90. PubMed ID: 9657446
[TBL] [Abstract][Full Text] [Related]
36. Agonist-induced desensitization of human β3-adrenoceptors expressed in human embryonic kidney cells.
Michel-Reher MB; Michel MC
Naunyn Schmiedebergs Arch Pharmacol; 2013 Oct; 386(10):843-51. PubMed ID: 23756578
[TBL] [Abstract][Full Text] [Related]
37. Modulatory effect of the adrenergic system upon fibroblast proliferation: participation of beta 3-adrenoceptors.
Anesini C; Borda E
Auton Autacoid Pharmacol; 2002 Jun; 22(3):177-86. PubMed ID: 12452903
[TBL] [Abstract][Full Text] [Related]
38. Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist.
Takusagawa S; Yajima K; Miyashita A; Uehara S; Iwatsubo T; Usui T
Xenobiotica; 2012 Oct; 42(10):957-67. PubMed ID: 22509825
[TBL] [Abstract][Full Text] [Related]
39. Splitomicin suppresses human platelet aggregation via inhibition of cyclic AMP phosphodiesterase and intracellular Ca++ release.
Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
Thromb Res; 2009 Jun; 124(2):199-207. PubMed ID: 19327818
[TBL] [Abstract][Full Text] [Related]
40. Platelet beta-adrenoceptors.
Kerry R; Scrutton MC
Br J Pharmacol; 1983 Jul; 79(3):681-91. PubMed ID: 6140045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
